Responsive and activable nanomedicines for remodeling the tumor microenvironment

Yinlong Zhang, Xuexiang Han, Guangjun Nie

Published: 2020-12-10 DOI: 10.1038/s41596-020-00421-0

tumor microenvironment

nanomedicines

platelets

stellate cells

drug delivery

AI 解读

Efficient and safe single-cell cloning of human pluripotent stem cells using the CEPT cocktail

Profiling native pulmonary basement membrane stiffness using atomic force microscopy

Genetic circuit design automation with Cello 2.0

Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages

Scalable dual-omics profiling with single-nucleus chromatin accessibility and mRNA expression sequencing 2 (SNARE-seq2)

A practical guide to scanning light-field microscopy with digital adaptive optics

Effective high-throughput isolation of fully human antibodies targeting infectious pathogens

Improved sampling and DNA extraction procedures for microbiome analysis in food-processing environments

MOF-derived nanoporous carbons with diverse tunable nanoarchitectures

Tutorial: a statistical genetics guide to identifying HLA alleles driving complex disease

查看全部

Sections

Figures

References

Here we describe two protocols for the construction of responsive and activable nanomedicines that regulate the tumor microenvironment (TME). The TME is composed of all non-cellular and cellular components surrounding a tumor, including the surrounding bl
Introduction
Materials
Procedures
Troubleshooting
Timing
Anticipated results
- References
References
ACKNOWLEDGMENTS
ACKNOWLEDGMENTS

Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98–101 (1989).
Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
Zhang, F. et al. Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies. Cancer Res. 78, 3718–3730 (2018).
Balkwill, F. R., Capasso, M. & Hagemann, T. The tumor microenvironment at a glance. J. Cell Sci. 125, 5591–5596 (2012).
Ji, T. J., Zhao, Y., Ding, Y. P. & Nie, G. J. Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications. Adv. Mater. 25, 3508–3525 (2013).
Belli, C. et al. Targeting the microenvironment in solid tumors. Cancer Treat. Rev. 65, 22–32 (2018).
Yuan, Y., Jiang, Y. C., Sun, C. K. & Chen, Q. M. Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol. Rep. 35, 2499–2515 (2016).
Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71–78 (2004).
Shimizu, K. et al. Immune suppression and reversal of the suppressive tumor microenvironment. Int. Immunol. 30, 445–454 (2018).
Wu, T. & Dai, Y. Tumor microenvironment and therapeutic response. Cancer Lett. 387, 61–68 (2017).
Diop-Frimpong, B. et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl Acad. Sci. USA 108, 2909–2914 (2011).
Niu, Y. M. et al. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles. J. Control. Release 277, 35–47 (2018).
Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941–951 (2015).
Li, W. & Sun, X. Recent advances in developing novel anti-cancer drugs targeting tumor hypoxic and acidic microenvironments. Recent Pat. Anticancer Drug Discov. 13, 455–468 (2018).
Sharma, A. et al. Hypoxia-targeted drug delivery. Chem. Soc. Rev. 48, 771–813 (2019).
Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52–67 (2010).
Mahzouni, P. & Sarmadi, T. An observational study on the expression of cyclooxygenase-2 in meningioma. Adv. Biomed. Res. 3, 211 (2014).
Lu, Y., Aimetti, A. A., Langer, R. & Gu, Z. Bioresponsive materials. Nat. Rev. Mater. 2, 16075 (2017).
Pelaz, B. et al. Diverse applications of nanomedicine. ACS Nano 11, 2313–2381 (2017).
Golombek, S. K. et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv. Drug Deliv. Rev. 130, 17–38 (2018).
Liu, J. J., Chen, Q., Feng, L. Z. & Liu, Z. Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement. Nano Today 21, 55–73 (2018).
Li, S. et al. Nanoparticle-mediated local depletion of tumour-associated platelets disrupts vascular barriers and augments drug accumulation in tumours. Nat. Biomed. Eng. 1, 667–679 (2017).
Han, X. et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem. Nat. Commun. 9, 3390 (2018).
Ovais, M., Guo, M. & Chen, C. Tailoring nanomaterials for targeting tumor-associated macrophages. Adv. Mater. 31, e1808303 (2019).
Miao, L. et al. Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors. Cancer Res. 77, 719–731 (2017).
Ho-Tin-Noe, B., Demers, M. & Wagner, D. D. How platelets safeguard vascular integrity. J. Thromb. Haemost. 9, 56–65 (2011).
Neesse, A., Algul, H., Tuveson, D. A. & Gress, T. M. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut 64, 1476–1484 (2015).
Demers, M. et al. Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 71, 1540–1549 (2011).
Zhang, Y. L. et al. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics 7, 1062–1071 (2017).
Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719–734 (2014).
Ho-Tin-Noe, B. et al. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 68, 6851–6858 (2008).
Volz, J. et al. Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice. Blood 133, 2696–2706 (2019).
Demers, M. & Wagner, D. D. Targeting platelet function to improve drug delivery. Oncoimmunology 1, 100–102 (2012).
Bergmeier, W. et al. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood 95, 886–893 (2000).
Lee, Y. & Thompson, D. H. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 9, 1450 (2017).
Meng, H. et al. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano 9, 3540–3557 (2015).
Dangi-Garimella, S. et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 71, 1019–1028 (2011).
Fan, Y., Li, C., Li, F. & Chen, D. pH-activated size reduction of large compound nanoparticles for in vivo nucleus-targeted drug delivery. Biomaterials 85, 30–39 (2016).
Wang, H. et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32, 8281–8290 (2011).
Elbakry, A. et al. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett. 9, 2059–2064 (2009).
Ding, C., Gu, J., Qu, X. & Yang, Z. Preparation of multifunctional drug carrier for tumor-specific uptake and enhanced intracellular delivery through the conjugation of weak acid labile linker. Bioconjug. Chem. 20, 1163–1170 (2009).
Long, A. H. et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4, 869–880 (2016).
Mirza, N. et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66, 9299–9307 (2006).
Song, W. J. et al. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small 6, 239–246 (2010).
Park, K. M. et al. All-trans-retinoic acid (ATRA)-grafted polymeric gene carriers for nuclear trans and cell growth control. Biomaterials 30, 2642–2652 (2009).
Swartz, M. A. et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 72, 2473–2480 (2012).
Li, H., Qiu, Z. W., Li, F. & Wang, C. L. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol. Lett. 14, 5865–5870 (2017).
Salem, N. et al. High expression of matrix metalloproteinases: MMP-2 and MMP-9 predicts poor survival outcome in colorectal carcinoma. Future Oncol. 12, 323–331 (2016).
Zheng, H. C. et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 26, 3579–3583 (2006).
Trudel, D. et al. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res. 63, 8511–8515 (2003).
Han, X. et al. An extendable star-like nanoplatform for functional and anatomical imaging-guided photothermal oncotherapy. ACS Nano 13, 4379–4391 (2019).
Kanamala, M. et al. Dual pH-sensitive liposomes with low pH-triggered sheddable PEG for enhanced tumor-targeted drug delivery. Nanomedicine (Lond). 14, 1972–1990 (2019).
Li, H. J. et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc. Natl Acad. Sci. USA 113, 4164–4169 (2016).
Bachem, M. G. et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 115, 421–432 (1998).

Responsive and activable nanomedicines for remodeling the tumor microenvironment

推荐阅读